



SPAFID
CONNECT

Informazione Regolamentata n. 0957-67-2021	Data/Ora Ricezione 02 Novembre 2021 19:56:49	Euronext Milan
--	--	----------------

Societa' : DiaSorin

Identificativo : 153589

Informazione
Regolamentata

Nome utilizzatore : DIASORINN01 - Spada - Vaccarone

Tipologia : 2.4

Data/Ora Ricezione : 02 Novembre 2021 19:56:49

Data/Ora Inizio : 02 Novembre 2021 19:56:50

Diffusione presunta

Oggetto : CONCLUSION OF THE TREASURY
SHARES BUY-BACK PLAN OF DIASORIN
S.P.A.

Testo del comunicato

Please see attachments.



CONCLUSION OF THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN S.P.A.

Saluggia, November 2nd, 2021 – DiaSorin announces the positive conclusion, on November 2nd, 2021, of the buy-back plan, started on April 6th, 2021, of 100.000 common shares, equal to 0,178% of the Company's share capital for a total value of Euro 16,466,146.31, for the purposes of the share incentive plans named "*DiaSorin S.p.A. 2020 Stock Option Plan*" and "*DiaSorin S.p.A. 2021 Stock Option Plan*", under the terms and provisions authorized by the Shareholders Meeting dated June 10th, 2020.

Following the above purchases and considering the treasury shares already in portfolio, at the date hereof DiaSorin S.p.A. holds no. 1,210,200.00 treasury shares, equal to 2.1631% of the share capital.

For details on operations performed and any other requirement provided by the applicable Law please refer to the weekly press already released as per the Delegated Regulation (EU) no. 2016/1052, available on the Company's website www.diasoringroup.com (Section Investors/Press releases)

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39.0161.487567

emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasoringroup.com

Fine Comunicato n.0957-67

Numero di Pagine: 3